Evidence map›Paper›PMID 36342104›Full record

ArticleThe oncologist2023

SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.

David K Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana and 16 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04427280 (Cancer), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04427280 completednot on this map

Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)

TypeobservationalSponsorRoyal Marsden NHS Foundation TrustRan2020 to 2021Enrolled153ConditionsInfectious Disease, Cancer, Coronavirus InfectionArmsThroat/nose swabs, Saliva collection, Blood collection
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Vaccines for preventing infections in adults with solid tumours.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 3 countries.

David K LauGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Maria AresuDepartment of Clinical Research and Development, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Timothy PlancheCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Amina TranDepartment of Clinical Research and Development, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Retchel Lazaro-AlcausiGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Julie DuncanGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Shannon KiddGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Susan CromartyGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Ruwaida BegumGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Isma RanaGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Su LiGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Ali Abdulnabi SuwaidanGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Irene MonahanCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
David J ClarkCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Nicholas EckersleyCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Henry M StainesCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Elisabetta GroppelliCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Sanjeev KrishnaCentre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.
Martin Mayora-NetoViral Pseudotype Unit (VPU Kent), Medway School of Pharmacy, University of Kent and Greenwich at Medway, Chatham Maritime, Kent, UK.
Nigel TempertonViral Pseudotype Unit (VPU Kent), Medway School of Pharmacy, University of Kent and Greenwich at Medway, Chatham Maritime, Kent, UK.ORCID 0000-0002-7978-3815
Charlotte FribbensGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
David WatkinsGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Naureen StarlingGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.ORCID 0000-0002-1496-6792
Ian ChauGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.ORCID 0000-0003-0286-8703
David CunninghamGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Sheela RaoGastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, UK.
Royal Marsden NHS Foundation Trust · GBSt George's, University of London · GBMedway School of Pharmacy · GB

Funding

Wellcome Trust 204809/Z/16/Z
6 · The paper itself

Abstract

introductionPatients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination. MATERIALS AND

methodsBetween September 2020 and April 2021, patients with cancer undergoing chemotherapy were enrolled. At baseline (day 0), days 28, 56, and 84, we assessed serum antibodies to SARS-CoV-2 spike (anti-S) and anti-nucleocapsid (anti-NP) and concomitantly assessed virus neutralization using a pseudovirus neutralization assay. Patients received either the Pfizer/BioNTech BNT162b2, or the Oxford/AstraZeneca ChAdOx1 vaccine.

resultsAll 152 patients enrolled had a prior diagnosis of cancer; colorectal (n = 80, 52.6%), oesophagogastric (n = 38, 25.0%), and hepato pancreatic biliary (n = 22, 12.5%). Nearly all were receiving systemic anti-cancer therapy (99.3%). Of the 51 patients who did not receive a vaccination prior to, or during the study, 5 patients had detectable anti-NP antibodies. Ninety-nine patients received at least one dose of vaccine prior to, or during the study. Within 19 days following the first dose of vaccine, 30.0% had anti-S detected in serum which increased to 70.2% at days 20-39. In the 19 days following a second dose, anti-S positivity was 84.2% (32/38). However, pseudovirus neutralization titers (pVNT80) decreased from days 20 to 39.

conclusionDespite the immunosuppressive effects of chemotherapy, 2 doses of SARS-CoV-2 vaccines are able to elicit a protective immune response in patients' ongoing treatment for gastrointestinal cancers. Decreases in pseudoviral neutralization were observed after 20-39 days, re-affirming the current recommendation for vaccine booster doses. CLINICAL TRIAL REGISTRATION NUMBER: NCT04427280.

Indexed as

COVID-19COVID-19 VaccinesGastrointestinal NeoplasmsImmunogenicity, VaccineAntibodiesBNT162 VaccineHumansProspective StudiesSARS-CoV-2AntibodiesBNT162 VaccineCOVID-19 Vaccinesanti-spikechemotherapyCOVID-19gastrointestinal cancerimmunitypseudovirusSARS-CoV-2vaccines

Identifiers

PMID36342104
PMCPMC9847553
OpenAlexW4308370370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.